{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:19:02Z","timestamp":1792397942368,"version":"4.4.0"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This post hoc analysis of all\u2010case post\u2010marketing surveillance in Japanese patients with rheumatoid arthritis assessed risk factors for major adverse cardiovascular events (MACE), malignancies, and serious infections (SI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data of patients who received tofacitinib (\u2265\u20091 dose) were stratified by each combination of age (&lt;\u200950\u2009years and \u2265\u200950\u2009years) and the number of cardiovascular (CV) risk factors (0 or \u2265\u20091). Incidence rates (IRs) of each adverse event (AE)\u2010MACE, malignancies, and SI, stratified by age, CV risk factors, and patient background factors were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 7021 patients were stratified by each combination of age (&lt;\u200950 and \u2265\u200950\u2009years) and the number of CV risk factors (0 or \u2265\u20091). The IRs for malignancies and SI were higher in patients aged \u2265\u200950 vs. &lt;\u200950\u2009years. The IRs for all AEs were higher in patients with \u2265\u20091 CV risk factors than 0 CV risk factors. Older age was strongly correlated with all AEs. MACE and SI were more likely to be affected by any CV risk factors, while the other AE was influenced by some of them.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Older age was a risk factor for all AEs (MACE, malignancies, and SI). MACE risk was also increased in patients with \u2265\u20091 CV risk factors versus those without. SI risk might also be increased in patients with \u2265\u20091 CV risk factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1756-185x.70572","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T04:37:06Z","timestamp":1770698226000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk Factors for Major Adverse Cardiovascular Events, Malignancies, and Serious Infections With Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of a 3\u2010Year J\u2010Post\u2010Marketing Surveillance"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8858-9435","authenticated-orcid":false,"given":"Kunihiro","family":"Yamaoka","sequence":"first","affiliation":[{"name":"Department of Rheumatology Kitasato University School of Medicine  Sagamihara Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Hoshi","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Endo","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D Japan G.K  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2932-6375","authenticated-orcid":false,"given":"Toshitaka","family":"Hirano","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0728-9"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22783"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1682776"},{"key":"e_1_2_11_5_1","unstructured":"\u201cXELJANZ (Tofacitinib Citrate) \u201daccessed May 6 2025 https:\/\/www.pfizer.com\/news\/press\u2010release\/press\u2010release\u2010detail\/xeljanz_tofacitinib_citrate_approved_in_japan_for_the_treatment_of_adults_with_rheumatoid_arthritis_ra."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33383"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24567"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33419"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.995875"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20494"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40803"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0932-2"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130683"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1866-2"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222405"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222543"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223715"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/road063"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.15448"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roaf017"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X231201047"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185x.70572","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185x.70572","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185x.70572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T21:35:04Z","timestamp":1773005704000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185x.70572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/1756-185x.70572"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.70572","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-10-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70572"}}